Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Company Announcement no. 26/2016
To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 20 December 2016
Veloxis Pharmaceuticals Announces Financial Calendar for 2017
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced its financial calendar for 2017.
29 March, 2017: 2016 Annual Report.
7 April, 2017: 2017 Annual General Meeting.
16 May, 2017: Q1 Interim Report – for the period 1 January to 31 March, 2017.
16 August, 2017: Q2 Interim Report – for the period 1 January to 30 June, 2017.
14 November, 2017: Q3 Interim Report – for the period 1 January to 30 September, 2017.
For more information, please contact:
Craig Alexander Collard
President & CEO
Phone: +1 919 591 3065
Email: [email protected]
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
Attachments:http://www.globenewswire.com/NewsRoom/AttachmentNg/541b8815-bce1-4a91-828e-c684383bc1e6
